Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cenerimod. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 known ✓ | P21453 | 20/20 | 1.00 |
| ▸ | S1PR3 | Q99500 | 19/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2670846 | 1.00 | S1PR1 (1.00) | S1PR1S1PR3 | |
| Cenerimod SCHEMBL2670989 | 1.00 | S1PR1 (1.00) | S1PR1S1PR3 | |
| SCHEMBL2670878 | 1.00 | S1PR1 (1.00) | S1PR1S1PR3 | |
| Cenerimod SCHEMBL2670991 | 1.00 | S1PR1 (1.00) | S1PR1S1PR3 | |
| SCHEMBL2670844 | 1.00 | S1PR1 (1.00) | S1PR1S1PR3 | |
| Cenerimod SCHEMBL2671193 | 1.00 | S1PR1 (1.00) | S1PR1S1PR3 | |
| Cenerimod SCHEMBL29439050 | 1.00 | S1PR1 (1.00) | S1PR1S1PR3 | |
| SCHEMBL2671090 | 0.99 | S1PR1 (0.98) | S1PR1S1PR3 | |
| SCHEMBL2671089 | 0.99 | S1PR1 (0.98) | S1PR1S1PR3 | |
| SCHEMBL11302274 | 0.93 | S1PR1 (0.87) | S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114573574-A | Crystalline form of a compound | 爱杜西亚药品有限公司 | 2022-06-03 | — | — | CN | claimed |
| EP-4587005-A1 | SIP 1 RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF TYPE 1 IFN MEDIATED DISEASES | Viatris Asia Pacific Pte. Ltd. (SG) | 2025-07-23 | — | — | EP | disclosed |
| WO-2025083549-A1 | METHODS AND COMBINATIONS OF INHIBITORS OF IL-23 PATHWAY AND MODULATORS OF S1P SIGNALING PATHWAY FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) | 2025-04-24 | — | — | WO | disclosed |
| EP-4463154-A1 | COMBINATION OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE AND ITS DERIVATIVES WITH A S1P RECEPTOR MODULATOR | ABIVAX (FR) | 2024-11-20 | — | — | EP | disclosed |
| CN-118900691-A | Combination of 8-chloro-N- (4- (trifluoromethoxy) phenyl) quinolin-2-amine and derivatives thereof with S1P receptor modulators | ABIVAX公司 | 2024-11-05 | — | — | CN | disclosed |
| CN-118662488-A | Therapeutic agent for myalgic encephalomyelitis/chronic fatigue syndrome | 田边三菱制药株式会社 | 2024-09-20 | — | — | CN | disclosed |
| CN-114980874-B | Therapeutic agent for myalgic encephalomyelitis/chronic fatigue syndrome | 田边三菱制药株式会社 | 2024-08-13 | — | — | CN | disclosed |
| CN-114573574-B | Crystalline forms of a compound | 爱杜西亚药品有限公司 | 2024-06-11 | — | — | CN | disclosed |
| WO-2024056631-A1 | S1P 1 RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF TYPE 1 IFN MEDIATED DISEASES | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-03-21 | — | — | WO | disclosed |
| WO-2023135207-A1 | COMBINATION OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE AND ITS DERIVATIVES WITH A S1P RECEPTOR MODULATOR | ABIVAX (FR) | 2023-07-20 | — | — | WO | disclosed |
| EP-4051250-A1 | COMBINATION OF A CXCR7 ANTAGONIST WITH AN S1P1 RECEPTOR MODULATOR | Idorsia Pharmaceuticals Ltd (CH) | 2022-09-07 | — | — | EP | disclosed |
| CN-114980874-A | Therapeutic agent for myalgic encephalomyelitis/chronic fatigue syndrome | 田边三菱制药株式会社 | 2022-08-30 | — | — | CN | disclosed |
| CN-114599363-A | Combinations of CXCR7 antagonists with S1P1 receptor modulators | 爱杜西亚药品有限公司 | 2022-06-07 | — | — | CN | disclosed |
| CN-114573574-A | Crystalline form of a compound | 爱杜西亚药品有限公司 | 2022-06-03 | — | — | CN | disclosed |
| CN-107667104-B | Crystalline forms of (S) -3- {4- [5- (2-cyclopentyl-6-methoxy-pyridin-4-yl) - [1,2,4] oxadiazol-3-yl ] -2-ethyl-6-methyl-phenoxy } -propane-1, 2-diol | 爱杜西亚药品有限公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-107667104-B | Crystalline forms of (S) -3- {4- [5- (2-cyclopentyl-6-methoxy-pyridin-4-yl) - [1,2,4] oxadiazol-3-yl ] -2-ethyl-6-methyl-phenoxy } -propane-1, 2-diol | 爱杜西亚药品有限公司 | 2022-03-22 | — | — | CN | disclosed |